Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

213.94 -2.42 (-1.12%)
Streaming Delayed Price Updated: 2:31 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
19 20 Next >
News headline image
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Recap: Natera Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Preview For Natera ↗
 
Via Benzinga
News headline image
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
From Natera, Inc.
Via Business Wire
News headline image
Disney, Natera, Chubb And A Major Tech Stock On CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust said Natera, Inc. 
Via Benzinga
News headline image
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
From Natera, Inc.
Via Business Wire
News headline image
A Glimpse Into The Expert Outlook On Natera Through 9 Analysts ↗
 
Via Benzinga
News headline image
There are signs that NASDAQ:NTRA may be ready to breakout. ↗
NATERA INC (NASDAQ:NTRA) has a good technical rating of 10 out of 10 and could possibly break out. 
Via Chartmill
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
From Natera, Inc.
Via Business Wire
News headline image
Agilent Technologies Stock Getting Closer To Key Technical Benchmark ↗
Agilent Technologies stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 65 to 71. 
Via Investor's Business Daily
News headline image
Wall Street Takes A Breather As Inflation Stays Tamed, AMD Hits Record Highs, Apple Struggles: What's Driving Markets Thursday? ↗
Wall Street exhaled a sigh of relief as the Federal Reserve’s favored gauge of inflation cooled as anticipated in January, quelling fears that an unexpected rise in the Consumer Price Index (CPI) might... 
Via Benzinga
Topics Economy
News headline image
Natera to Participate in March Investor Conferences
From Natera, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold ↗
On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades. 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2024 ↗
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
News headline image
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
From Natera, Inc.
Via Business Wire
News headline image
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
From Natera, Inc.
Via Business Wire
News headline image
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List ↗
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
News headline image
NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy ↗
NVTA stock tumbled yesterday amid a report that the firm could declare bankruptcy soon. The shares were halted for news pending. 
Via InvestorPlace
Topics Bankruptcy
News headline image
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy ↗
Invitae's financial challenges as it grapples with a $1.5 billion debt burden. Explore the company's strategic options amidst potential bankruptcy, asset shedding, and cost-cutting measures. 
Via Benzinga
Topics Bankruptcy
News headline image
Pinterest, Checkpoint Therapeutics And 2 Other Stocks Insiders Are Selling ↗
The Nasdaq 100 closed higher by around 300 points on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
New Study Validates Signatera™ in Endometrial Cancer
From Natera, Inc.
Via Business Wire
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
From Natera, Inc.
Via Business Wire
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.